Rxsight Earnings Reports

RxSight, Inc. reported a strong fourth quarter with a 41% increase in revenue compared to the same period last year. The growth was fueled by increased sales of Light Adjustable Lenses (LAL) and Light Delivery Devices (LDD). The company reaffirmed its 2025 guidance, projecting continued revenue growth and stable gross margins.

RxSight reported a strong third quarter with a 59% increase in revenue compared to the same period last year, driven by increased sales of Light Adjustable Lenses (LAL) and Light Delivery Devices (LDD). The company also raised its full-year revenue guidance and increased its gross margin guidance.

RxSight, Inc. reported a significant increase in revenue for the second quarter of 2024, driven by strong sales of Light Adjustable Lenses (LAL) and Light Delivery Devices (LDD). The company's revenue grew by 68% compared to the same period last year, with a notable increase in gross profit. Despite increased operating expenses, the net loss was reduced compared to the previous year.

RxSight, Inc. reported a strong start to 2024, with first-quarter revenue increasing by 69% to $29.5 million compared to the previous year. The growth was driven by increased sales of Light Adjustable Lenses (LAL) and Light Delivery Devices (LDD). The company's net loss decreased to $(9.1) million, and adjusted net loss also improved. RxSight increased its full-year revenue, gross margin and operating expense guidance.

RxSight, Inc. reported a strong fourth quarter in 2023, with a 78% increase in revenue compared to the same period in 2022. This growth was fueled by increased sales of LDDs and LALs. The company's gross profit also saw a substantial increase, although it reported a net loss for the quarter.

RxSight reported strong third-quarter results with a 76% increase in revenue to $22.2 million, driven by increased sales of Light Delivery Devices (LDD) and Light Adjustable Lenses (LAL). The company also increased its full-year 2023 guidance range for revenue and gross margin.

RxSight, Inc. reported strong second-quarter results with significant revenue growth driven by increased sales of Light Delivery Devices (LDD) and Light Adjustable Lenses (LAL), leading to an improved full-year outlook.

RxSight, Inc. reported a strong first quarter in 2023, marked by a 96% increase in revenue compared to the same period last year. The company saw growth in both LDD and LAL sales, increased its gross margin, and reiterated its operating expense guidance for the year.

RxSight, Inc. reported a strong fourth quarter with a 91% increase in revenue compared to Q4 2021, driven by increased sales of Light Delivery Devices (LDDs) and Light Adjustable Lenses (LALs). The company's installed base of LDDs expanded significantly, and LAL procedure volumes more than tripled. The company provided revenue guidance for 2023 between $78.0 million and $83.0 million.

RxSight, Inc. reported a significant increase in revenue for the third quarter of 2022, with a 118% increase compared to the third quarter of 2021. The growth was driven by increases in both LDD and LAL revenue. The company has revised its 2022 full-year revenue guidance to a range of $47.0 million to $48.0 million.

RxSight, Inc. reported a significant increase in revenue for the second quarter of 2022, driven by strong demand for its Light Delivery Devices (LDD) and Light Adjustable Lenses (LAL). The company's revenue grew by 132% compared to the same quarter last year. The company has revised its 2022 full year revenue guidance to a range of $44.0 million to $46.0 million.

RxSight, Inc. reported a strong start to 2022 with a 157% increase in revenue compared to the first quarter of 2021, driven by increased sales of Light Delivery Devices and Light Adjustable Lenses. The company has revised its 2022 full year revenue guidance to a range of $41.5 million to $45.5 million.

RxSight, Inc. reported a 71% increase in revenue for the fourth quarter of 2021, reaching $8.4 million, driven by growth in LDD and LAL sales. The company's gross profit increased to $2.9 million, but it experienced a net loss of $15.7 million due to increased operating expenses.

RxSight reported Q3 2021 revenue of $5.8 million, a 39% increase compared to Q3 2020. The revenue growth was primarily due to a 55% increase in LDDs sold and a 31% increase in LALs sold. Net loss for the quarter was $(12.7) million, or $(0.68) per share.

RxSight reported second quarter 2021 revenue of $4.9 million, representing growth of 81% compared to the prior year period. The growth was primarily driven by increased LDD and LAL unit sales and a more favorable market environment because of the reduced impact from the COVID-19 pandemic. Net loss was $(13.5) million, or $(3.28) and $(3.53) per share on a basic and diluted basis, respectively.